anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Administer BANZEL with food. BANZEL film-coated tablets can be administered whole, as half tablets or crushed.

BANZEL oral suspension should be shaken well before every administration. The provided adapter and calibrated oral dosing syringe should be used to administer the oral suspension. The adapter which is supplied in the product carton should be inserted firmly into the neck of the bottle before use and remain in place for the duration of the usage of the bottle. The dosing syringe should be inserted into the adapter and the dose withdrawn from the inverted bottle. The cap should be replaced after each use. The cap fits properly when the adapter is in place [see Patient Counseling Information (17)].
Patients will receive 3 applications of low intensity light directly in the region of the three pairs of salivary glands already described. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The first application will be after the stimulated collection of saliva and the following applications will be given once a week for another 2 weeks.
SARS-CoV-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as Post-COVID. To understand how the virus might effect the working of the Immune system a large observational study of health insurance data from Germany was set up. The exposed patients were identified by a diagnosis indicating a confirmed laboratory test for COVID-19.

The basic question concerns the burden of the Post-COVID condition. The study investigate which autoimmune diseases or groups of autoimmune diseases are more common in humans after the exposure to the virus compared to a matched unexposed cohort. Further will this be investigated in subgroups of the population.
This project brings together the expertise of investigators at three centers to develop and conduct a pilot test of a new comprehensive intervention to increase the quality of educational services and access to inclusive settings for students with autism spectrum disorder (ASD) in elementary school (kindergarten through 5th grade). The intervention model, Students with Autism Accessing General Education (SAAGE), integrates evidence-based strategies to teach skills to students with ASD in schools, best practices derived from this literature by the project investigators, a recent guidebook written by the principal investigator, and research on collaboration with community providers such as school teams to implement interventions efficaciously and sustainably. SAAGE begins with strategies to help a school form a cohesive team to oversee implementation of the model in the school. For each student, SAAGE uses a modular approach for identifying goals for a student, selecting appropriate teaching strategies, and systematically monitoring progress and trouble-shooting. The modules center on core and associated features of ASD. Study personnel will use well established behavioral skills training procedures to coach educators to implement the modules.
BACKGROUND: Inflammation has been reported to be related to anemia. As a novel inflammatory marker, Systemic immune-inflammation index (SII) has not been studied with Anemia. The aim of this study was to investigate the possible relationship between SII and anemia.
METHODS: This retrospective cross-sectional survey was conducted using data from the 2005-2018 National Health and Nutrition Examination Survey (NHANES) population. In total, 19851 American adults aged ≥18 years were included. SII was calculated as the platelet count×neutrophil count/lymphocyte count. Anemia was defined as hemoglobin (Hgb) levels of < 13 g/dL in males and < 12 g/dL in females. Logistic regression analyses, subgroup analyses and sensitivity analyses were performed to investigate the relationship between SII and anemia.
RESULTS: Our study included a total of 19851 patients, of which 1501 (7.6%) had anemia. After adjusting for all covariates, the multivariate logistic regression analysis showed that a higher SII (In-transform) level was associated with increased likelihood of anemia (OR=1.51, 95% CI: 1.36-1.68, P<0.001). The association between SII and anemia exhibited a nonlinear manner. The positive correlation between SII and anemia was related to the severity of anemia. Subgroup analysis showed that there was no significant dependence on age, family income, body mass index, hypertension, kidney disease and cancer except gender on this positive association. Furthermore, sensitivity analyses confirmed the robustness of our results.
CONCLUSION: Our study demonstrated that SII was positively associated with anemia especially among female participants. And this positive correlation was related to the severity of anemia. Further large-scale prospective studies are still needed to analyze the role of SII in anemia.
PURPOSE:To obtain a side effect remover containing L-carnosine or a salt thereof as an active ingredient for a chemotherapeutic agents having inhibitory action on biosynthesis of nucleic acid. CONSTITUTION:The aimed substance obtained by containing L-carnosine or a salt thereof as an active ingredient and preparing a pharmaceutical by a conventional method. The remover can be prepared in a form, such as injection, powder, granule, tablet, capsule, enteric agent or troche. The dose thereof is 1-20ml intravenously injected as an injection or 1-5g administered in 3 divided portions a day in the case of powder for oral administration. Drugs requiring removal of side effects by the L-carnosine are chemotherapeutic agents, etc., capable of preventing propagation of cancer, AIDS virus, etc., and this remover is capable of removing side effects of the drugs, such as leukopenia caused by inhibitory action on biosynthesis of nucleic acid. Thereby the original action of the chemotherapeutic agents can be exhibited. The L-carnosine is a substance, resembling foods, having high safety and synthesized by a well-known method.
Zanthoxylum myriacanthum var. pubescens essential oil and an extract comprising the zanthoxylum myriacanthum var. pubescens essential oil. The zanthoxylum myriacanthum var. pubescens essential oil is a volatile substance extracted from zanthoxylum myriacanthum var. pubescens. Zanthoxylum myriacanthum var. pubescens, the zanthoxylum myriacanthum var. pubescens essential oil or the extract comprising the zanthoxylum myriacanthum var. pubescens essential oil are used for the treatment of diabetes and the protection of the pancreas structure, the liver structure or the kidney structure, and can be used for the preparation of a drug or functional foodstuff. The zanthoxylum myriacanthum var. pubescens essential oil can recover the morphology and function of â cells, i.e., the zanthoxylum myriacanthum var. pubescens essential oil can recover the morphology and function of â cells whilst lowering blood glucose. Therefore, the zanthoxylum myriacanthum var. pubescens essential oil is of great value in the commercial market.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract, and surgery is the preferred treatment method for primary resectable GIST. The guidelines recommend that patients at high risk of recurrence should be treated with tyrosine kinase inhibitors (TKI) such as imatinib for at least 3 years after surgery. However, in actual clinical practice, some patients face the situation of early withdrawal or prolonged medication, so the timing of drug withdrawal needs to be further studied. Recent studies have reported that some GIST patients who have achieved disease control through long-term use of imatinib can still achieve a long progression-free survival after drug withdrawal, and those who relapse after drug withdrawal can still achieve disease control after re-use of imatinib. This suggests that for some selected patients, a "drug holiday" treatment mode could be possible, in which drugs are discontinued when appropriate and restarted if necessary. How to select patients suitable for this mode of treatment needs further exploration. Liquid biopsy of peripheral blood circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) can be used for the diagnosis, efficacy evaluation, recurrence and drug resistance monitoring of a variety of malignant tumors. Existing studies have explored the "drug holiday" treatment mode based on MRD detection assisting patients with advanced non-small cell lung cancer to use TKI. Therefore, this one-arm prospective observational clinical study will assist some high-risk GIST patients who have been treated with imatinib for 3 years after surgery and have achieved disease control to adopt the treatment mode of "drug holiday" based MRD detection, aiming to evaluate the value of MRD detection in monitoring postoperative recurrence of high-risk GIST, investigate the effect of "drug holiday" treatment mode based on MRD detection on disease recurrence and patient survival, and to explore whether it can delay the occurrence of drug-resistant mutations.
PCT No. PCT/SE90/00207 Sec. 371 Date Aug. 15, 1991 Sec. 102(e) Date Aug. 15, 1991 PCT Filed Mar. 30, 1990.The present invention relates to a method to manufacture a composite ceramic material having a high strength combined with bioactive properties, when the material is used as a dental or orthopedic implant, which includes preparing a powder mixture, mainly comprising partly a first powder, which in its used chemical state will constitute a bioinert matrix in the finished material , and partly a second powder, mainly comprising a calcium phosphate-based material. The invention is characterized in that said first powder comprises at least one of the oxides belonging to the group consisting of titanium dioxide (TiO2), zirconium oxide (ZrO2) and aluminum oxide (Al2O3), in that said second powder mainly comprises at least one of the compounds hydroxylapatite and tricalcium phosphate, in that a raw compact is made of said powder mixture and in that said raw compact is densified through an isostatic pressing in a hot condition (HIP) at a pressure higher than 50 MPa, a composite material being obtained, in which said matrix comprises one or several metal oxides of said first powder, in which matrix said compound hydroxylapatite and/or tricalcium phosphate is evenly dispersed. The invention also relates to a composite ceramic material as well as a body, completely or partially made of this material.
BACKGROUND: In small cell lung cancer (SCLC), the pathological N category is identical to it in non-small cell lung cancer (NSCLC) and remains unchanged over a decade. Here we verified the discriminability of number of involved nodal stations (nS) in SCLC and compared its efficacy in predicting survival with currently used pathological nodal (pN) staging.
METHODS: We retrospectively analyzed the patients who received operations and were pathologically diagnosed as SCLC at Shanghai Pulmonary Hospital between 2009 and 2019. X-tile software was adopted to determine optimal cut-off values for nS groups. Kaplan-Meier method and Cox regression analysis were used to compare survival between different groups. Decision curve analysis (DCA) was employed to evaluate the standardized net benefit.
RESULTS: A total of 369 patients were included. The median number of sampled stations was 6 (range 3-11), and the median number of positive stations was 1 (range 0-7). The optimal cutoff for nS groups was: nS0 (no station involved), nS1-2 (one or two stations involved), and nS ≥ 3 (three or more stations involved). Overall survival (OS) and relapse-free survival (RFS) were statistically different among all adjacent categories within the nS classification (p < 0.001, for both OS and RFS between each two subgroups), but survival curves for subgroups in pN overlapped (OS, p = 0.067; RFS, p = 0.068, pN2 vs. pN1). After adjusting for other confounders, nS was a prognostic indicator for OS and RFS. The DCA revealed that nS had improved predictive capability than pN.
CONCLUSIONS: Our cohort study demonstrated that the nS might serve as a superior indicator to predict survival than pN in SCLC and was worth considering in the future definition of the N category.
Participants in this arm will only complete the baseline assessment and 2 month assessment. They will not receive Enhanced Project Health.
BACKGROUND: Dairy contains a complex mixture of lipids, proteins, and micronutrients. Whether habitual dairy consumption is associated with health benefits is not well established. Since dairy is high in nutrients that are potentially protective against frailty, the association between dairy products and the risk of frailty is of interest.
METHODS: We analyzed data from 85,280 women aged ≥ 60 years participating in the Nurses' Health Study. Consumption of milk, yogurt, and cheese was obtained from repeated food frequency questionnaires administered between 1980 and 2010. Frailty was defined as having at least three of the following five criteria from the FRAIL scale: fatigue, low strength, reduced aerobic capacity, having ≥ 5 chronic illnesses, and a weight loss of ≥ 5%. The occurrence of frailty was assessed every four years from 1992 to 2018. Cox proportional hazard models were used to examine the association between the intake of dairy foods and frailty.
RESULTS: During follow-up we identified 15,912 incident cases of frailty. Consumption of milk or yogurt was not associated with the risk of frailty after adjustment for lifestyle factors, medication use, and overall diet quality. Cheese consumption was positively associated with risk of frailty [relative risk (95% confidence interval) for one serving/day increment in consumption: 1.10 (1.05, 1.16)]. Replacing one serving/day of milk, yogurt, or cheese with one serving/day of whole grains, nuts, or legumes was associated with a significant lower risk of frailty, while replacing milk, yogurt, or cheese with red meat or eggs was associated with an increased risk. When milk was replaced with a sugar-sweetened or artificially sweetened beverage, a greater risk of frailty was observed, while replacing milk with orange juice was associated with a lower risk of frailty.
CONCLUSIONS: The results suggest that the association between milk, yogurt, and cheese and frailty partly depends on the replacement product. Habitual consumption of milk or yogurt was not associated with risk of frailty, whereas cheese consumption may be associated with an increased risk.
Patients in the MR+TE group will undergo 12 sessions (3 d/week) of sub-occipital inhibition treatment as a combined muscle and soft tissue inhibition technique. The physiotherapist will apply deep pressure which will be maintained for a total of 10 minutes until the sub-occipital tissues are released. In addition to this technique, the method of pumping and manual treatment (acupressure) of the trigger points on the sub-occipital muscles, on the upper bundles of the trapezius bilaterally, on the sternocleidomastoid bilaterally and on the scalene muscles bilaterally will be applied for a further 10 minutes for a total treatment with myofascial release equal to 20 minutes. At the end of the MR session, the 20-minute TE session will be performed in the same way as described in the TE intervention group.
PURPOSE:To produce a versatile antibody specific to T cell-type tumor by producing a monoclonal anti-human T cell receptor idiotype antibody using a specific hybridoma. CONSTITUTION:An antibody-producing cell collected from the spleen of a mouse immunized with a human T cell-type leukemia cell strain is fused with a mouse myeloma cell to obtain an antibody-producing hybridoma. The obtained hybridoma is selectively grown on a HAT-containing medium and screened to obtain a hybridoma capable of producing human T cell receptor idiotype monoclonal antibody (anti-hTcR-MoAb). The hydridoma is cultured in a liquid medium or in the abdominal cavity of a thymectomized nude mouse. The antibody-containing liquid is centrifuged and the MoAb is separated from the supernatant liquid and purified. The obtained MoAb is suitable as a biopharmaceutical which can be administered to human as a remedy or missile therapeutic agent.
The present invention provides an antibody which catalyzes hydrolysis of .beta.-amyloid at a predetermined amide linkage. The antibody preferentially binds a transition state analog which mimics the transition state adopted by .beta.-amyloid during hydrolysis at a predetermined amide linkage. Specific antibodies provided include those which catalyze the hydrolysis at the amyloid linkages between residues 39 and 40, 40 and 41, and 41 and 42 of .beta.-amyloid. The present antibody also provides a vectorized antibody which is characterized by the ability to cross the blood brain barrier and also catalyze the hydrolysis of .beta.-amyloid. Also provided are methods for sequestering free .beta.-amyloid in the blood stream, for reducing levels of .beta.-amyloid in the brain, for reducing the level of circulating .beta.-amyloid, for preventing the formation of amyloid plaques in the rain and for disaggregating amyloid plaques. Finally, this invention also provides a method of generating antibodies by immunizing an animal with antigen comprised of an epitope which has a statine analog or which utilizes reduced peptide bond analogs to mimic the conformation of a hydrolysis transition state of a polypeptide.
Objective.We aim to assess the severity of spatial neglect (SN) through detailing patients' field of view (FOV) using EEG. Spatial neglect, a prevalent neurological syndrome in stroke patients, typically results from unilateral brain injuries, leading to inattention to the contralesional space. Commonly used Neglect detection methods like the Behavioral Inattention Test-conventional lack the capability to assess the full extent and severity of neglect. Although the Catherine Bergego Scale provides valuable clinical information, it does not detail the specific FOV affected in neglect patients.Approach.Building on our previously developed EEG-based brain-computer interface system, AR-guided EEG-based neglect detection, assessment, and rehabilitation system (AREEN), we aim to map neglect severity across a patient's FOV. We have demonstrated that AREEN can assess neglect severity in a patient-agnostic manner. However, its effectiveness in patient-specific scenarios, which is crucial for creating a generalizable plug-and-play system, remains unexplored. This paper introduces a novel EEG-based combined spatio-temporal network (ESTNet) that processes both time and frequency domain data to capture essential frequency band information associated with SN. We also propose a FOV correction system using Bayesian fusion, leveraging AREEN's recorded response times for enhanced accuracy by addressing noisy labels within the dataset.Main results.Extensive testing of ESTNet on our proprietary dataset has demonstrated its superiority over benchmark methods, achieving 79.62% accuracy, 76.71% sensitivity, and 86.36% specificity. Additionally, we provide saliency maps to enhance model explainability and establish clinical correlations.Significance.These findings underscore ESTNet's potential combined with Bayesian fusion-based FOV correction as an effective tool for generalized neglect assessment in clinical settings.
Asthma drug responses may differ due to inflammatory mechanisms triggered by the immune cells in the pulmonary microenvironment. Thus, asthma phenotyping based on the local inflammatory profile may aid in treatment definition and the identification of new therapeutic targets. Here, we investigated protein profiles of induced sputum and serum from asthma patients classified into eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic asthma, according to inflammatory phenotypes. Proteomic analyses were performed using an ultra-performance liquid chromatography (ultra-HPLC) system coupled to the Q Exactive Hybrid Quadrupole Orbitrap Mass Spectrometer. Fifty-two (52) proteins showed significant differences in induced sputum among the groups, while only 12 were altered in patients' sera. Five proteins in the induced sputum were able to discriminate all phenotypic groups, while four proteins in the serum could differentiate all except the neutrophilic from the paucigranulocytic inflammatory pattern. This is the first report on comparative proteomics of inflammatory asthma phenotypes in both sputum and serum samples. We have identified a potential five-biomarker panel that may be able to discriminate all four inflammatory phenotypes in sputum. These findings not only provide insights into potential therapeutic targets but also emphasize the potential for personalized treatment approaches in asthma management.
Inflammation and skeletal homeostasis are closely intertwined. Inflammatory diseases are associated with local and systemic bone loss, and post-menopausal osteoporosis is linked to low-level chronic inflammation. Phosphoinositide-3-kinase signalling is a pivotal pathway modulating immune responses and controlling skeletal health. Mice deficient in Src homology 2-containing inositol phosphatase 1 (SHIP1), a negative regulator of the phosphoinositide-3-kinase pathway, develop systemic inflammation associated with low body weight, reduced bone mass, and changes in bone microarchitecture. To elucidate the specific role of the immune system in skeletal development, a genetic approach was used to characterise the contribution of SHIP1-controlled systemic inflammation to SHIP1-dependent osteoclastogenesis. Lymphocyte deletion entirely rescued the skeletal phenotype in Rag2 -/- /Il2rg -/- /SHIP1 -/- mice. Rag2 -/- /Il2rg -/- /SHIP1 -/- osteoclasts, however, displayed an intermediate transcriptomic signature between control and Rag2 +/+ /Il2rg +/+ /SHIP1 -/- osteoclasts while exhibiting aberrant in vitro development and functions similar to Rag2 +/+ /Il2rg +/+ /SHIP1 -/- osteoclasts. These data establish a cell-intrinsic role for SHIP1 in osteoclasts, with inflammation as the key driver of the skeletal phenotype in SHIP1-deficient mice. Our findings demonstrate the central role of the immune system in steering physiological skeletal development.
These patients will receive placebo orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.